Leiomyomas Clinical Trials

A clinical trial is enrolling patients with Uterine Fibroids.

The primary objective of this study is to show superiority of vilaprisan in the treatment of heavy menstrual bleeding (HMB) in subjects with uterine fibroids compared to placebo. The secondary objectives of this study are to additionally evaluate the efficacy and safety of vilaprisan in subjects with uterine fibroids.

Consider a research study for uterine fibroids. The Asteroid Studies are research studies evaluating the safety and effectiveness of an investigational oral medication for uterine fibroids.

To determine the benefit of relugolix 40 mg once daily co-administered with low dose estradiol and norethindrone acetate compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids

To demonstrate the superior efficacy versus placebo of OBE2109 alone and in combination with add-back therapy for the reduction of heavy menstrual bleeding associated with uterine fibroids in premenopausal women 

To assess the safety and efficacy of elagolix 300 mg BID in combination with E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg QD) compared to placebo at 1 year in reducing heavy menstrual bleeding associated with uterine fibroids in premenopausal women 

If you have been living with heavy periods due to uterine fibroids, participating in a research study may be an option. The Asteroid Studies are research studies evaluating the safety and effectiveness of an investigational oral medication for uterine fibroids.

A research study for women with heavy menstrual bleeding associated with uterine fibroids.

This is phase 3b study seeks to evaluate the safety and efficacy of elagolix in combination with estradiol/norethindrone acetate for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. This study is double-blinded in the first year and an open-label in the second year.

The purpose of this study is to determine the benefit and safety of relugolix 40 mg once daily co-administered with low dose estradiol and norethindrone acetate compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids. Additionally, this study is designed to evaluate the benefit of ...